[1]BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries ［J］.CA Cancer J Clin,2018,68(6):394-424.
[2]SIMMS KT,STEINBERG J,CARUANA M,et al.Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries,2020-99:A modelling study ［J］.Lancet Oncol,2019,20(3):394-407.
[3]PERKINS RB,GUIDO RS,CASTLE PE,et al.2019 asccp risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors ［J］.J Low Genit Tract Dis,2020,24(2):102-131.
[4]AO C, ZENG K.The role of regulatory T cells in pathogenesis and therapy of human papillomavirus-related diseases,especially in cancer ［J］.Infect Genet Evol,2018,65:406-413.
[5]THOMAS TL.Cancer prevention:Hpv vaccination ［J］.Semin Oncol Nurs,2016,32(3):273-280.
[6]SENKOMAGO V,HENLEY SJ,THOMAS CC,et al.Human papillomavirus-attributable cancers-United States,2012-2016 ［J］.Morb Mortal Wkly Rep,2019,68(33):724-728.
[7]BASSAL R,GUILBURD Y,SHAPIRA H,et al.The clinical significance of Hpv type in women with recurrent cytological Atypia ［J］.Isr Med Assoc J,2018,20(3):172-175.
[8]DE SANJOSE S,QUINT WG,ALEMANY L,et al.Human papillomavirus genotype attribution in invasive cervical cancer:a retrospective cross-sectional worldwide study ［J］.Lancet Oncol,2010,11(11):1048-1056.
[9]LAX SF,HORN LC, LONING T. Categorization of uterine cervix tumors:what's new in the 2014 who classification ［J］.Pathologe,2016,37(6):573-584.
[10]CURRY SJ,KRIST AH,OWENS DK,et al.Screening for cervical cancer:us preventive services task force recommendation statement ［J］.JAMA,2018,320(7):674-686.
[11]SALAZAR KL,DUHON DJ,OLSEN R,et al.A review of the FDA-approved molecular testing platforms for human papillomavirus ［J］.J Am Soc Cytopathol,2019,8(5):284-292.
[12]DEMARCO M,HYUN N,CARTER-POKRAS O,et al.A study of type-specific Hpv natural history and implications for contemporary cervical cancer screening programs ［J］.E Clinical Medicine,2020,22:100293.
[13]CASTLE PE,KINNEY WK,XUE X,et al.Role of screening history in clinical meaning and optimal management of positive cervical screening results ［J］.J Natl Cancer Inst,2019,111(8):820-827.
[14]HUH WK,AULT KA,CHELMOW D,et al.Use of primary high-risk human papillomavirus testing for cervical cancer screening:interim clinical guidance ［J］.Gynecol Oncol,2015,136(2):178-182.
[15]FONTHAM ETH,WOLF AMD,CHURCH TR,et al.Cervical cancer screening for individuals at average risk:2020 guideline update from the American cancer society ［J］.CA Cancer J Clin,2020,70(5):321-346.
[16]GOODMAN A.Hpv testing as a screen for cervical cancer ［J］.Bmj,2015,350:h2372.
[17] MAO YN,YOU ZX.Interpretation of the ASCCP 2019 consensus guidelines for the management of abnormal cervical cancer screening results ［J］.Progress in Obstetrics and Gynecology,2021,30(01):58-64.
[18] HUNAG C,LI WM.Advances in the application of aptamer molecular probe in tumor research ［J］.Oncology Progress,2019,17(04):373-375,414.
[19]HAN SX,JIA X,MA JL,et al.Molecular Beacons:a novel optical diagnostic tool ［J］.Arch Immunol Ther Exp(Warsz),2013,61(2):139-148.
[20]TAKACS T,JENEY C,KOVACS L,et al.Molecular beacon-based real-time PCR method for detection of 15 high-risk and 5 low-risk HPV types ［J］.J Virol Methods,2008,149(1):153-162.
[21]WANG L,BLASIC JR,JR HOLDEN MJ,et al.Sensitivity comparison of real-time pcr probe designs on a model DNA plasmid ［J］.Anal Biochem,2005,344(2):257-265.
[22]KEEGAN H,PILKINGTON L,MCINERNEY J,et al.Human papillomavirus detection and genotyping,by Hc2,full-spectrum hpv and molecular beacon real-time Hpv Assay in an Irish colposcopy clinic ［J］.J Virol Methods,2014,201:93-100.
[23]WONG YP,OTHMAN S,LAU YL,et al.Loop-mediated isothermal amplification(LAMP):a versatile technique for detection of micro-organisms ［J］.J Appl Microbiol,2018,124(3):626-643.
[24]MUDHIGETI N,KALAWAT U,HULIKAL N,et al.Evaluation of loop-mediated isothermal amplification assay for detection and typing of human papilloma virus 16 and 18 from endocervical samples ［J］.Indian J Med Microbiol,2019,37(2):241-247.
[25]SATOH T,MATSUMOTO K,FUJII T,et al.Rapid genotyping of carcinogenic human papillomavirus by loop-mediated isothermal amplification using a new automated dna test(clinichip Hpv)［J］.J Virol Methods,2013,188(1-2):83-93.
[26]ZHANG H,HU X,FU X.Aptamer-based microfluidic beads array sensor for simultaneous detection of multiple analytes employing multienzyme-linked nanoparticle amplification and quantum dots labels ［J］.Biosens Bioelectron,2014,57:22-29.
[27]WANG R,ZHAO R,LI Y,et al.Rapid detection of multiple respiratory viruses based on microfluidic isothermal amplification and a real-time colorimetric method ［J］.Lab Chip,2018,18(22):3507-3515.
[28]WANG Y,GE G,MAO R,et al.Genotyping of 30 kinds of cutaneous human papillomaviruses by a multiplex microfluidic loop-mediated isothermal amplification and visual detection method ［J］.Virol J,2020,17(1):99.
[29]KRAFFT C,SCHMITT M,SCHIE IW,et al.Label-free molecular imaging of biological cells and tissues by linear and nonlinear raman spectroscopic approaches ［J］.Angew Chem Int Ed Engl,2017,56(16):4392-4430.
[30]WOOLFORD L,CHEN M,DHOLAKIA K,et al.Towards automated cancer screening:label-free classification of fixed cell samples using wavelength modulated raman spectroscopy ［J］.J Biophotonics,2018,11(4):e201700244.
[31]TRAYNOR D,DURAIPANDIAN S,BHATIA R,et al.The potential of biobanked liquid based cytology samples for cervical cancer screening using raman spectroscopy ［J］.J Biophotonics,2019,12(7):e201800377.
[32]WU X,PENG Y,DUAN X,et al.Homologous gold nanoparticles and nanoclusters composites with enhanced surface raman scattering and metal fluorescence for cancer imaging ［J］.Nanomaterials(Basel),2018,8(10):819.
[33]JESS PR,SMITH DD,MAZILU M,et al.Early detection of cervical neoplasia by raman spectroscopy ［J］.Int J Cancer,2007,121(12):2723-2728.
[34]HU Z,MA D.The precision prevention and therapy of hpv-related cervical cancer:new concepts and clinical implications ［J］.Cancer Med,2018,7(10):5217-5236.